GMAB Stock Overview
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.2,660.00|
|52 Week High||kr.3,124.00|
|52 Week Low||kr.1,863.00|
|1 Month Change||-1.12%|
|3 Month Change||8.62%|
|1 Year Change||-4.49%|
|3 Year Change||97.26%|
|5 Year Change||87.32%|
|Change since IPO||1,041.63%|
Recent News & Updates
Do Genmab's (CPH:GMAB) Earnings Warrant Your Attention?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
|GMAB||DK Biotechs||DK Market|
Return vs Industry: GMAB exceeded the Danish Biotechs industry which returned -7% over the past year.
Return vs Market: GMAB exceeded the Danish Market which returned -8.3% over the past year.
|GMAB Average Weekly Movement||4.5%|
|Biotechs Industry Average Movement||7.9%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DK Market||10.5%|
|10% least volatile stocks in DK Market||3.1%|
Stable Share Price: GMAB is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: GMAB's weekly volatility (5%) has been stable over the past year.
About the Company
|1999||1,445||Jan G.J. van Winkel||https://www.genmab.com|
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.
Genmab Fundamentals Summary
|GMAB fundamental statistics|
Is GMAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GMAB income statement (TTM)|
|Cost of Revenue||kr.0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 09, 2022
|Earnings per share (EPS)||60.74|
|Net Profit Margin||38.81%|
How did GMAB perform over the long term?See historical performance and comparison
Is GMAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GMAB?
Other financial metrics that can be useful for relative valuation.
|What is GMAB's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does GMAB's PE Ratio compare to its peers?
|GMAB PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ALK B ALK-Abelló
300122 Chongqing Zhifei Biological Products
Price-To-Earnings vs Peers: GMAB is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the peer average (40.7x).
Price to Earnings Ratio vs Industry
How does GMAB's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: GMAB is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the European Biotechs industry average (34.3x)
Price to Earnings Ratio vs Fair Ratio
What is GMAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||43.8x|
|Fair PE Ratio||34.4x|
Price-To-Earnings vs Fair Ratio: GMAB is expensive based on its Price-To-Earnings Ratio (43.8x) compared to the estimated Fair Price-To-Earnings Ratio (34.4x).
Share Price vs Fair Value
What is the Fair Price of GMAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GMAB (DKK2660) is trading below our estimate of fair value (DKK7843.37)
Significantly Below Fair Value: GMAB is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Genmab forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GMAB's forecast earnings growth (21.9% per year) is above the savings rate (0.1%).
Earnings vs Market: GMAB's earnings (21.9% per year) are forecast to grow faster than the Danish market (9.2% per year).
High Growth Earnings: GMAB's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: GMAB's revenue (18.3% per year) is forecast to grow faster than the Danish market (6.7% per year).
High Growth Revenue: GMAB's revenue (18.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GMAB's Return on Equity is forecast to be low in 3 years time (18.3%).
Discover growth companies
How has Genmab performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GMAB has a high level of non-cash earnings.
Growing Profit Margin: GMAB's current net profit margins (38.8%) are higher than last year (34.3%).
Past Earnings Growth Analysis
Earnings Trend: GMAB's earnings have grown significantly by 25.8% per year over the past 5 years.
Accelerating Growth: GMAB's earnings growth over the past year (57.7%) exceeds its 5-year average (25.8% per year).
Earnings vs Industry: GMAB earnings growth over the past year (57.7%) exceeded the Biotechs industry -16.7%.
Return on Equity
High ROE: GMAB's Return on Equity (16.2%) is considered low.
Discover strong past performing companies
How is Genmab's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: GMAB's short term assets (DKK25.5B) exceed its short term liabilities (DKK1.9B).
Long Term Liabilities: GMAB's short term assets (DKK25.5B) exceed its long term liabilities (DKK1.1B).
Debt to Equity History and Analysis
Debt Level: GMAB is debt free.
Reducing Debt: GMAB has not had any debt for past 5 years.
Debt Coverage: GMAB has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GMAB has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Genmab current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Genmab Dividend Yield vs Market|
|Market Bottom 25% (DK)||1.8%|
|Market Top 25% (DK)||6.7%|
|Industry Average (Biotechs)||2.2%|
|Analyst forecast in 3 Years (Genmab)||0%|
Notable Dividend: Unable to evaluate GMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GMAB's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GMAB has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jan G.J. van Winkel (61 yo)
Dr. Jan G.J. van de Winkel, Ph D., served as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.Dr. Winkel is Director of LEO Pha...
CEO Compensation Analysis
|Jan G.J. van Winkel's Compensation vs Genmab Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||kr.38m||kr.8m|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||kr.37m||kr.7m|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||kr.35m||kr.7m|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||kr.28m||kr.7m|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||kr.27m||kr.7m|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||kr.23m||kr.6m|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||kr.20m||kr.5m|
Compensation vs Market: Jan G.J. van's total compensation ($USD5.05M) is above average for companies of similar size in the Danish market ($USD3.02M).
Compensation vs Earnings: Jan G.J. van's compensation has been consistent with company performance over the past year.
Experienced Management: GMAB's management team is considered experienced (3.6 years average tenure).
Experienced Board: GMAB's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Genmab A/S's employee growth, exchange listings and data sources
- Name: Genmab A/S
- Ticker: GMAB
- Exchange: CPSE
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr.173.510b
- Shares outstanding: 65.23m
- Website: https://www.genmab.com
Number of Employees
- Genmab A/S
- Kalvebod Brygge 43
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GNMS.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Oct 2000|
|GMAB||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Ordinary Shares||DK||DKK||Oct 2000|
|GE9||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Oct 2000|
|GE9||XTRA (XETRA Trading Platform)||Yes||Ordinary Shares||DE||EUR||Oct 2000|
|0MGB||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||DKK||Oct 2000|
|GMABC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||DKK||Oct 2000|
|GMAB||WBAG (Wiener Boerse AG)||Yes||Ordinary Shares||AT||EUR||Oct 2000|
|GMAB N||BMV (Bolsa Mexicana de Valores)||Yes||Ordinary Shares||MX||MXN||Oct 2000|
|GMAB||NasdaqGS (Nasdaq Global Select)||SPON ADR EACH REP 0.1 ORD SHS||US||USD||May 2013|
|GE91||BST (Boerse-Stuttgart)||SPON ADR EACH REP 0.1 ORD SHS||DE||EUR||May 2013|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/05 00:00|
|End of Day Share Price||2022/10/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.